Other · developed by Humacyte Global
Symvess is an acellular tissue engineered vessel composed of human extracellular matrix. It is designed to function as a vascular conduit for arterial repair and can support cell binding and proliferation.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 9, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07762794 | Phase 4 | Vascular Injury | Not yet recruiting | HUMA |
| NCT07762313 | Phase 3 | Vascular Trauma | Not yet recruiting | HUMA |
| NCT05908084 | Phase 3 | End Stage Renal Disease (ESRD) | Active not recruiting | HUMA |
| NCT02644941 | Phase 3 | Renal Failure | Completed | HUMA |
| NCT04135417 | Phase 2 | Renal Failure | Completed | HUMA |
| NCT05873959 | N/A | Trauma | Completed | HUMA |
| NCT03631056 | N/A | Vascular System Injuries | Approved for marketing | HUMA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Arterial BleedingArterial InjuryEnd Stage Renal Disease (ESRD)Vascular InjuryVascular TraumaEnd Stage Renal DiseaseHemodialysisRenal FailureTraumaTrauma BluntTrauma InjuryTrauma, MultipleVascular AccessVascular System Injuries
Updated Oct 3, 2026. Something wrong or missing? Report it on the HUMA page.
See HUMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HUMA catalysts and pipeline →